ReviewOncoTargets and therapy2015
The distinctive nature of adenocarcinoma of the lung.
Review in OncoTargets and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Investigation of sphingolipid-related genes in lung adenocarcinoma.Frontiers in molecular biosciences · 2025Article
- Bioinformatics analysis revealsTranslational cancer research · 2024Article
- Neuroendocrine Differentiation of Lung Cancer Cells Impairs the Activation of Antitumor Cytotoxic Responses in Mice.International journal of molecular sciences · 2023Article
- High expression of 14-3-3ơ indicates poor prognosis and progression of lung adenocarcinoma.Oncology letters · 2022Article
- The Role of Mitochondrial miRNAs in the Development of Radon-Induced Lung Cancer.Biomedicines · 2022Review
- Integrative Analysis of the Expression of SIGLEC Family Members in Lung Adenocarcinoma via Data Mining.Frontiers in oncology · 2021Article
- Outcome prediction in resectable lung adenocarcinoma patients: value of CT radiomics.European radiology · 2020Article
- Analysis of genes associated with prognosis of lung adenocarcinoma based on GEO and TCGA databases.Medicine · 2020Article
- Methylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer.Oncology letters · 2020Article
- Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?Journal of thoracic disease · 2018Article
- Santamarine Inhibits NF-BioMed research international · 2017Article
- Rac3 Regulates Cell Invasion, Migration and EMT in Lung Adenocarcinoma through p38 MAPK Pathway.Journal of Cancer · 2017Article
- Diagnostic MicroRNA Biomarker Discovery for Non-Small-Cell Lung Cancer Adenocarcinoma by Integrative Bioinformatics Analysis.BioMed research international · 2017Article
- Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma.Oncotarget · 2016Article
- Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery.British journal of cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib and ceritinib are two new tyrosine kinase inhibitors directed against the echinoderm microtubule-like protein 4-anaplastic lymphoma kinase translocation. The possibility of these new molecules being used to treat patients without adenocarcinoma histology is notably small. For example, EGFR mutations and anaplastic lymphoma kinase fusion gene rearrangement are rare in patients with squamous cell carcinoma (generally <1%). Additionally, the benefit of targeted treatment approaches in patients with small-cell lung cancer histology is limited. All of these findings highlight the distinctive nature of adenocarcinoma of the lung among all lung cancer subtypes. Unfortunately, to date, less than 15% of patients with adenocarcinoma of the lung are ideal candidates for these targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.